Brindha G Sankaran¹*, Manimekalai K¹, Mukul M Barwant² and Mudasir A Dar³

¹Assistant Professor, Department of Biotechnology, Hindusthan College of Arts and Science, Coimbatore, India
²Department of Botany, Sanjivani Arts, Commerce and Science College Kopargaon, Maharashtra India
³Biofuels Institute, School of Environment and Safety Engineering, Jiangsu University, Zhenjiang, China

*Corresponding Author: Brindha G Sankaran, Assistant Professor, Department of Biotechnology, Hindusthan College of Arts and Science, Coimbatore, India.

Received: April 25, 2024; Published: April 30, 2024

Abstract

Polycystic ovarian syndrome (PCOS) presents a multifaceted clinical picture, characterized by hyperandrogenism, ovarian dysfunction, and metabolic disturbances, including insulin resistance and dyslipidemia. Within this complex landscape, anti-Müllerian hormone (AMH) emerges as a key player, reflecting ovarian reserve and serving as a prognostic marker for fertility. This study aimed to elucidate the phenotypic and genotypic spectrum of AMH (rs10407022) and LHCGR (rs13405728) in PCOS among South Indian women, leveraging a cohort of 600 subjects diagnosed according to Rotterdam criteria. Hardy-Weinberg Equilibrium analysis facilitated gene-gene interaction exploration. Our investigation revealed a noteworthy presence of the TT allele variant of AMH rs10407022 in 18 individuals within the PCOS cohort. Furthermore, LHCGR rs13405728 exhibited four instances of the CC allele variant. These findings underscore the significance of AMH and LHCGR gene polymorphisms in PCOS pathogenesis and folliculogenesis among South Indian women, offering insights into the genetic underpinnings of this complex endocrine disorder.

Keywords: PCOS; AMH; LHCGR; Folliculogenesis Allelic Frequency; Single Nucleotide Polymorphism

References

1. Taghavi M and Fatemi S. “Macroprolactinemia accompany in patients with hyperandrogenemic symptoms”. Iranian Journal of Endocrinology and Metabolism 10 (2008): 273-276.
2. Mohammad M B and Seghinsara AM. “Polycystic ovary syndrome (PCOS) diagnostic criteria, and AMH”. Asian Pacific Journal of Cancer Prevention: APJCP1 (2017): 17.
3. Hiam D., et al. “The genetics of polycystic ovary syndrome: an overview of candidate gene systematic reviews and genome-wide association studies”. Journal of Clinical Medicine10 (2019): 1606.
4. Malik S., et al. “Management of polycystic ovary syndrome in India”. Fertility Science and Research1 (2014): 23.
5. Rehman R., et al. “Interplay of leptin with obesity and polycystic ovarian syndrome’. Life Science Journal 4 (2022): 83-89.
6. Day F., et al. “Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria”. PLoS Genetics12 (2018): e1007813.
7. Wang F., et al. “The role of AMH and its receptor SNP in the pathogenesis of PCOS”. Molecular and Cellular Endocrinology 439 (2017): 363-368.
8. Yang Y., et al. “Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population”. Reproductive Biology and Endocrinology1 (2010): 1-7.
9. Essah PA., et al. “The metabolic syndrome in polycystic ovary syndrome”. Clinical Obstetrics and Gynecology1 (2007): 205-225.
10. Khalil Gerges N and Albiomy Khalefa A. “Serum nesfatin-1 levels in experimentally-induced polycystic ovary in lean and obese albino rats”. Al-Azhar Medical Journal4 (2016): 885-900.
11. Saddick SY. “Identifying genes associated with the development of human polycystic ovary syndrome”. Saudi Journal of Biological Sciences5 (2020): 1271-1279.
12. Haase M and Willenberg HS. “Hyperandrogenämie”. DMW-Deutsche Medizinische Wochenschrift49 (2013): 2509-2511.
13. Shen W., et al. “Calpain-10 genetic polymorphisms and polycystic ovary syndrome risk: a meta-analysis and meta-regression”. Gene2 (2013): 426-434.
14. Corbin K D., et al. “Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms”. Endocrine Reviews5 (2018): 629-663.
15. Giles LC., et al. “Growth trajectories in early childhood, their relationship with antenatal and postnatal factors, and development of obesity by age 9 years: results from an Australian birth cohort study”. International Journal of Obesity7 (2015): 1049-1056.
16. Lim SS., et al. “Lifestyle changes in women with polycystic ovary syndrome”. Cochrane Database of Systematic Reviews 3 (2019).
17. Knebel B., et al. “Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARγ gene variants”. Experimental and Clinical Endocrinology and Diabetes8 (2008): 481-486.
18. Ha L., et al. “Association study between polycystic ovarian syndrome and the susceptibility genes polymorphisms in Hui Chinese women”. PLoS One5 (2015).
19. Zou J., et al. “Association of luteinizing hormone/choriogonadotropin receptor gene polymorphisms with polycystic ovary syndrome risk: a meta-analysis”. Gynecological Endocrinology 1 (2019): 81-85.

Citation

Citation: Brindha G Sankaran., et al. “Genetic Polymorphic Associations of Anti-Mullerian Hormone and Luteinizing Hormone/Chorionic Gonadotropin Receptor in Women Suffering from Polycystic Ovarian Syndrome: Insights from South Indian Population".Acta Scientific Biotechnology 5.2 (2024): 34-42.

Copyright

Copyright: © 2024 Brindha G Sankaran., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.